John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his ...

Sci­ence 37, one of the star­tups that fu­eled the rise in de­cen­tral­ized clin­i­cal tri­als, will go pri­vate and see its one-time $1 bil­lion val­u­a­tion evap­o­rate … ...

HHS on Fri­day an­nounced its se­lec­tions for the next-gen­er­a­tion of Covid-19 vac­cine can­di­dates to re­ceive $500 mil­lion in fund­ing as part of the gov­ern­ment’s Project … ...

When ac­tor Bel­lamy Young was grow­ing up, her fa­ther suf­fered from a brain dis­or­der called he­pat­ic en­cephalopa­thy (HE) caused by cir­rho­sis of the liv­er. … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

The Fed­er­al Trade Com­mis­sion wants more in­for­ma­tion on Pfiz­er’s takeover of Seagen be­fore it will make a rul­ing on whether it will clear the … ...

Just a few days af­ter pric­ing a $150 mil­lion pub­lic of­fer­ing, Io­vance has now closed with 15% more raised, thanks to … ...

→ There’s a shake­up at the top of Chemomab Ther­a­peu­tics as the Is­raeli biotech halts the start of a Phase II study to save cash … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pfiz­er and Astel­las tout­ed more de­tailed da­ta over the week­end on their drug Xtan­di in a type of prostate can­cer, which the com­pa­nies say show … ...

A bill that re­quires the Di­rec­tor of Na­tion­al In­tel­li­gence to de­clas­si­fy new in­for­ma­tion on the ori­gins of Covid-19 passed the House … ...

When Pres­i­dent Joe Biden’s bud­get comes out on Thurs­day, ex­pect to see a big, po­ten­tial­ly mul­ti-bil­lion-dol­lar pro­pos­al to re­al­ly take a crack at cur­ing more … ...